Tilray Inc TLRY shares are trading higher following news the company purchased a majority position in amended Medmen Enterprises Inc MMNFF convertible notes for about $165.8 million.
Irwin D. Simon, Tilray's Chairman and CEO, said, "Backed by accelerating trends towards legalization globally, we are focused on building the world's leading cannabis-focused consumer branded company with a goal of $4 billion of revenue by the end of our fiscal 2024."
"The investment we are announcing in MedMen securities today, one of the most recognized brands in the $80 billion U.S. cannabis market, is a critical step towards delivering on our objective as we work to enable Tilray to lead the U.S. market when legalization allows," Simon stated.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of the company's sales are in Canada and in the international medical cannabis export market.
TLRY Price Action: The stock is trading higher by 4.2% to $13.67 after hours. Tilray has a 52-week high of $67 and a 52-week low of $4.41.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!